CP-751,871 Treatment For Patients With Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.

Key facts

Study ID

NCT01536145

Run by

Pfizer

People needed

47

Starts

2003-12-01

Expected to finish

2008-06-01

Last updated by the study team

2013-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL) and/or urine (≥ 200 mg/24-hr) paraprotein
• Adequate bone marrow, renal, liver and cardiac function
• Eastern Cooperative Oncology Group [ECOG] performance status less than or equal to 2

You may not qualify if…

• Prior allogeneic stem cell transplant (alloSCT)
• Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP-751,871
• Prior organ allograft
• Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors
• Female patients who are pregnant or lactating

Where it is running

• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Scottsdale, Arizona, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Rochester, Minnesota, United States
• Pfizer Investigational Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.